- Home
- SPRY
as 11-15-2024 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | 24 | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.53 - $18.51 | Next Earning Date: | 11-13-2024 |
| Revenue: | $2,568,000 | Revenue Growth: | 8460.00% |
| Revenue Growth (this year): | 21686.67% | Revenue Growth (next year): | 956.61% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Oct 15 '24 | Sell | $15.00 | 100,000 | $1,487,595.07 | 1,397,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Oct 15 '24 | Sell | $15.00 | 100,000 | $1,487,595.07 | 1,298,499 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Oct 8 '24 | Sell | $13.83 | 100,000 | $1,382,775.00 | 1,397,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Oct 8 '24 | Sell | $13.83 | 100,000 | $1,382,775.00 | 1,298,499 | |
| Karas Eric | SPRY | Chief Commercial Officer | Sep 18 '24 | Sell | $14.00 | 10,000 | $140,000.00 | 5,693 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Sep 17 '24 | Sell | $12.93 | 100,000 | $1,293,205.00 | 1,397,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Sep 17 '24 | Sell | $12.93 | 100,000 | $1,293,205.00 | 1,298,499 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Sep 10 '24 | Sell | $11.50 | 100,000 | $1,149,775.00 | 1,397,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Sep 10 '24 | Sell | $11.50 | 100,000 | $1,149,775.00 | 1,298,499 | |
| Thompson Peter A. | SPRY | Director | Aug 26 '24 | Sell | $13.00 | 83,695 | $1,088,035.00 | 0 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term
MT Newswires
3 days ago
ARS Pharmaceuticals Insider Sold Shares Worth $10,143,706, According to a Recent SEC Filing
GuruFocus.com
3 days ago
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...
Zacks
4 days ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
MT Newswires
4 days ago
ARS Pharmaceuticals' Q3 Net Loss Widens
GlobeNewswire
4 days ago
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
TipRanks
5 days ago
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy
Investor's Business Daily
6 days ago
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.